It has been identified to be effective on anaerobes, aerobes and protozoa that cause diarrhea, dysentery, enteritis, traveler’s diarrhea and acute food poisoning.
Mebatic Infusion has shown 20-25% improved efficacy over the existing therapies. The drug has been developed with a ‘chemical vector’ that promotes faster recovery and ensures deeper penetration of antibiotic at the site of infection.
Manu Chaudhary, director and head of Venus Medicine Research Center, said: “More effective and innovative therapies are needed as the micro-organism are becoming increasingly resistant to the existing antibiotics like Metronidazole. Due to the increased drug resistance mortality associated with anaerobes in India has gone up to 24-31%, which is indeed a cause of concern.”
The drug has been approved by the Drugs Controller General of India (DCGI) after successful phase II comparative clinical trials conducted by Venus Medicine Research Center, the R&D arm of Venus Remedies.